including you key made for corporate Thank I'll quarter call. performance, Today, we our XXXX achievements I'll call then Chief the call all XXXX start second open the across our before discussing for our outlook business Officer, over closing second who and and John have results Sprague, we by and earnings our Financial and joining three turn update quarter I priorities. to questions our will financial answers. review our remarks, for provide the
recently has achieved team number a key Biosystems TX milestones. of The
order breakthrough company XXX(k) We received month. designation received for quarterly designation record driven history. received We the FDA device auris the test, test applied Candida breakthrough the TXDx for device submission FDA we TXBiothreat FDA with orders. diagnostic sepsis a last quarter, the panel. for panel second the a During we filed second and largest in We from instrument sepsis
each University debt the on raising Medical with collaboration our by our that our of balance sepsis We progress important the Center. and represents providing pursue to We equity. development TXBacteria driving utilization and clinical expanding our of and market Vanderbilt CRG sheet initiatives. believe milestones increased opportunity by flexibility to of Panel strengthened growth portion capital adoption and these a products, established We a toward converting
needed. mission recent advancing all sepsis-related Our diagnostics culture accomplishments There sepsis, year, estimated hospitalization, independent deaths Sepsis of through of health more million our of change When way to comes U.S. improve area lives contribute world. number is practiced the toward medicine one fundamentally each believe our is our an annually. the drastic are to XX around main an we estimated cost are that $XX the it costing billion system focus, worldwide than changes cancers patients care combined. transformative the
XX one number number in days. XX,XXX the year causing XX% Americans death XX-day and within each the XXX,XXX are cause is cause and is of in treatment providers. to annually and be within U.S. more Current sepsis rehospitalized And sepsis to Sepsis the U.S., XX hospitals, be days hospice. payers causing rehospitalization of the in of one methods XX% patients, of failing rehospitalized death survivors die
hour X% resulting targeted shows antimicrobial longer delayed culture results to in up for positive of fungal by advantage a pathogens significant We believe Biosystems days result products five can to increase targeted hours. continue risk products X Data only time infections, competitors has just therapy. competitive one for TX able that detect blood on blood as to the causing reminder, a therapy. the in to antimicrobial As to take rely our delayed of can to that FDA-cleared sepsis each and from death X our directly have
our accelerating advance first priority, we our we're our more As our with three We'll our Starting each accelerating priorities: mission, operations sales. in these on pipeline. detail. of and advancing priorities sales, our corporate discuss enhancing focused
we second panel product million, period, volume. revenue a total quarterly the notably, of quarter, an the sepsis record quarter During compared the prior representing we order. achieved panel received order of revenue comprised Sepsis million, test $X.X back test ending was to X% And $XXX,XXX revenue. of $X.X despite increase year entirely with
the able panels June of been our would order test Had have as compared we period. back increased sepsis XX% sales to to of clear prior XX, year by the
significant our TXDx four and In which were the for U.S. sepsis executed XX quarterly seven test contracts addition the U.S. our There and were panel distribution our outside sepsis international orders, in second products by be our during to record of test continued reflected to markets, international Instruments to quarter, we the partners. in of a TXDx panels Instruments our continues commercial for opportunity sales
won for hospitals seven sale Our well second for results history, second our as distributors sepsis includes company's our the in of Instruments, orders contract quarter and largest to the sepsis extend to driven the our the of The hospitals as XXXX, additional in initial supply Panel Instruments is a included years term for TXDx two new products may and European our contract has be deployed instrument and that additional Panel. sepsis one occur satisfy three Poland. contract of to Poland, the nine TXCandida the sold during potential to an second test the potential panels, in years. to contract TXResistance half The to TXDx including the and for the TXBacteria Panel, which
severe A found XX of population of in ranging ICU believe reduced enable ICU and the and eight outcomes. stay faster the our targeted to more days. clinicians study antimicrobial product's detect XX% to and rates in can days achieve between one sepsis mortality making ICU of member populous We therapy, of ability rapidly over people, Poland states the has patient stay XX% a of to antibiotic from XX in X,XXX and in in genes length pathogens resistance improve and it causing most European the Poland Union sepsis the million length patients than hospitals.
distributors hospitals throughout our and our is our more increasing including economic Europe. that our by their clinical factors, affirm sepsis opportunity Increased belief products products adoption and deploy a Poland with of number an of being awareness utilization are value. of efforts our in of and there into number to to driven a European discussion increase Our significant of
Our commercial, on sepsis affairs medical and and service potential use hospital testing expanding customers closely identifying criteria in are teams educating protocols. and current cases, implementing testing aligned,
capability and the Medical we bloodstream for second opportunity believe top demonstrate a We to the collaboration TXBacteria Center Panel prospective to a one usage of clinical with interventions the the centers Panel data States. TXBacteria the value Vanderbilt antibiotic Panel of to this additional patients conduct quarter, our clinical implement academic in setting During the collaboration further medical Vanderbilt in will the TXDx to Instrument TXBacteria improve generate and announced United FDA-cleared with study. to evaluate and infection. an a provides clinical University a and of in assess
where We Microbiology around anticipate and studies in aid is team on leaders new library additional our medical European of in were opinion assist was Clinical Vanderbilt and by findings being world, the presented. continually clinical their further recent will the affairs ECCMID, published the at three study key and the education display as Diseases presented or from Society Infectious data efforts. Data
the Hospital, Their within At their shared independent Panel targets. Conference XX Panel. TXBacteria positive infections team patient key health as the that the having TXBacteria that use Panel X to broad of than their each Microbiology targeted culture-based Butler experience of as The for demonstrates patients case American to the system, the the hours has in as Butler presented part the leaders identified for blood of of faster coverage, population detects studies formed methods. Panel Panel in protocol TXBacteria TXBacteria allowed data newly hours much and Society with as June, laboratory TXBacteria developed well from a trigger the therapy showing X at
has reduction program, in our operations. We our number costs. for the implemented Moving significant to included second a company's important these which enhance to stands are structure, NASDAQ believe including XX%, steps of success, by of cost taken and strategic In steps reduction which and balance of including chain workforce supply our priority, our May, manufacturing. our our a employees operations, operating sheet, our essential listing. resulted We've nearly long-term enhancing now at XXX we restructuring a a
the equity, which we into CRG part converted equity our As strengthens as restructuring strong of XX% program, $XX sheet. view debt of our million the of a We support or debt balance approximately to from CRG. show of conversion
other options, acquisition, to including intent we merger, or reverse assets combination, a merger, we our announced early balance continue licensing, Finally, sheet sale in business significant since improvement which explore of explore despite to May. strategic our
sepsis of issues material our earnings customer sufficient we limited quarter volume meet test produce call, raw first ability our panels On that demand. to had to discussed
routine reminder, internal identified this was a inspection. As during in-process
to shipped not customers was distributors affected. that product or was a So
at the approximately that cleared While the order we existed with ended we the of order majority end the of first back of second $XXX,XXX. a the quarter quarter, back
changes of the capabilities, and of Vice to a hiring manufacturing back Operations, manufacturing controls raw purchase with a significant critical new of new consultant made to the our the engagement our expect that products. and We've including address of materials resolve order, we the experience improvements the President significant around advanced
our future order products. We from current our we test to customer and continue globe, back expect to panels to the demand distributor the the for demand around and hospitals have and for strong sepsis resolve meet
and with compliance Finally, provide minimum companies update least On minimum NASDAQ which securities those $XX plans. participated our $X price that and listed an compliance value to of in in both plans NASDAQ the listed of value and with on July maintain to presented stock requirements. rules securities, we require X, bid with appeal a The listed the price like regain I'd to has million hearing we the requested $X a all time regain million. Market compliance to NASDAQ market NASDAQ minimum our of on an $XX minimum at additional we maintain XXXX, bid to the Capital
with compliance plans our response, we appeal are that provided an We're report and the NASDAQ. a we the approving presented to until XX, regain November pleased extension Biosystems on and granting NASDAQ XXXX, to formal has the executing that TX to
third pipeline. our our advancing priority, to Moving
term, new significant to Near on in which comprehensive menu and developing test we're Our target rapid need panel. patient bioterrorism of unmet a represent our outcomes. we're sepsis product and disease, prioritizing treatment expansion sepsis, can term, Instrument. and medical FDA-cleared development improved next-generation test antimicrobial Longer areas which line faster targeted detection priorities instrument TXDx lead
intended therapy. our test Panel. to to antimicrobial developing test panel Acinetobacter products Panel, a our targeted or five test the and addition are the TXResistance potentially TXLyme differentiated the We these clinicians to including an expanding test TXBiothreat baumannii, will pathogens of instrument and a solution the test test Panel, the new test menu harmful believe with products achieve TXBacteria on new and Candida to FDA-cleared We auris new expand five the Instrument, identify increase existing Panel, utilization. Each represents menu both rapidly adoption allow TXDx faster
The typhus. Panel these as from treated of information hours is provide with biothreat patients. pathogens organisms pathogens that plague the biothreat six test directly within Instrument XX%. TXBiothreat able infections the The cause U.S. TXBiothreat blood Panel X blood result designed anthrax, for including appropriately pathogens or molecular direct with diagnostic to a treat clinicians If and is by detect Control and to mortality FDA-cleared XX% infected and to to TXDx glanders, these needed Disease can CDC, biothreat run detect rapidly in not promptly, on and simultaneously Centers from identified threats the Prevention, tularemia, rates
owned Panel the such will Panel. believe XXX(k) only an the discussions very regarding for the U.S. and the we high biothreat in XXXX. product developed blood be which for We direct factor sensitivity in think TXBiothreat and U.S. filed a company, product May demonstrates by FDA important of We multi-target clearance specificity submission a is TXBiothreat government early Panel TXBiothreat entities an with the purchases from for
with We the we on the positive a are actively FDA anticipate outcome. engaged submission and
CE resistance designed wait to hours direct as genes methicillin Mark The is known TXResistance X to for without vancomycin. common from blood is TXDx X may test resistance antibiotic-resistant the antimicrobials to diagnostic need Panel Panel, marketed resistance molecular a and genes to cause XX on in to just simultaneously FDA-cleared which antibiotic and such infections days that detect sold the and Europe under a carbapenems, TXResistance positive detects confer Instrument culture. run blood The in
completing internal including an We to have we advanced for and FDA the trial, clinical plan submission U.S. XXX(k) patient testing, stability after clearance testing. completing enrollment, including file additional
detect upon which contract FDA, diagnostic The TXDx by As is a review with auris breakthrough test TXResistance wait a species submission under from a need Instrument was the blood run X FDA-cleared in reminder, days hours on our to process the the to prioritized auris the blood and has granted direct and just without designed provides to X device test molecular funding Candida BARDA. a for culture. Panel for positive designation received Candida
life-threatening early -- with of Candida threat a and in fungal on are inappropriate called is up has professionals the burden Health benefits by auris public Organization. health to and by fungal has mortality detection identify is general, and health the a life-saving rate as help to as difficult that of as World and treatment. estimates Candida disease the multidrug-resistant is lead fungal to awareness $XX standard methods, laboratory diseases associated proper benefits billion pathogen XX% global the costs a sorry, U.S. can CDC continuing lower auris serious of recognized to the with raise to high annually CDC which treatment. of
and for As the we runs days Candida albicans, detect the culture. just to causing currently wait species, Candida need and Instrument Panel, blood and detects simultaneously a TXCandida fungal FDA-cleared glabrata. on from a X TXDx FDA-cleared test The Candida the the parapsilosis, five reminder, able TXCandida Candida Candida to hours sepsis krusei, in directly without only diagnostic positive including market Panel sell X pathogens tropicalis, to Candida blood
we improving access received pathogens these FDA which getting FDA Candida provides outcomes. to infected on pleased is Device recently as may FDA of test, targeted therapy essential clearance. antifungal report to detection I'm frequent that the designation greater the well and Rapid Breakthrough our for patients to auris path Candida more and auris as and patient to accelerate
a hours the FDA-cleared a wait TXBacteria expand just all is commonly to to baumannii our X blood bacterial test designed detection in the add of baumannii need days pathogen will Acinetobacter detect our Panel approximately baumannii capabilities. the to TXBacteria without blood baumannii to test for increase from Instrument tests and blood FDA-cleared Acinetobacter of on culture. sepsis-causing of the in The molecular culture. to addition The TXDx found direct to diagnostic Panel XX% Acinetobacter X plan positive capabilities to the We infections, Acinetobacter detection run
be septic Acinetobacter of rate half of XX%. including bloodstream to health shock, clearance, in an weakened immune during can infections, those patients, ICU baumannii with which of second rarely has from systems, critically and been resistant reported chronic and the can to bacteremia highlighting believe have diabetes. lung to for especially infections States detection plan and a range ill sufficient have the We many care in to XXX(k) cause Acinetobacter transit to outside antimicrobial crude that FDA settings we mortality and treatment. antibiotics, benign that the carbapenems, disease to impact occur data XX% file United targeted or of file importance XXXX. can Acinetobacter we rapid submission disproportionately
from the direct the on that to Instrument Panel cause test TXLyme intended TXDx run of bacteria disease and U.S. with burgdorferi, the FDA-cleared individuals the molecular detect a Lyme diagnostic is Panel major TXLyme Borrelia The blood create take to symptoms presence signs in designed and is of which the and The test can advantage in early will currently disease, the and to of of significant disease to that aid four testing diagnosis Lyme post-infection. serological we provide weeks Lyme requires recommended a antibodies, believe six over the the it body is
& of award for our Innovation up TXLyme Human total that to the Services between U.S. winner and public-private or the a Lyme plans to future Health the Accelerator award of largest and was a disease $X the partnership Cohen XXXX, Foundation, a million to winners. Panel In in Steven Alexandra LymeX, named partnership Department Lyme
designation for the received also allows for to review a FDA We prioritized process TXLyme breakthrough device the Panel, submission which FDA. upon
we for commercialization clearance. a We Panel We the plan and as development commenced assay believe support developed a TXLyme established have early a to ml. U.S. level subsequently CFU XXX(k) of clinical -- of for laboratory and initiate submission preliminary TXLyme detection trial per completed X test we of to the Panel, the
X with our longer-term under XX% by the The single antibiotic panel from of instrument test the approximately panel. been panel all a result have direct sepsis bloodstream developing of next-generation to to at ahead as sepsis caused funded is infections Candida and bacterial designed number test a genes detections We're single a from instrument Looking panel species to blood identified contract sample. test comprehensive whole and with is and by greater resistance increase BARDA. instrument designed in comprehensive test next-generation a next-generation CDC detect hours. comprehensive blood threats time sepsis The The and products. of a a than test
With detailed our updated financial now financial to Sprague John turn update results for XXXX. a of that, outlook I'll John? it provide quarter to second and our over
